Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 17,400 shares, a drop of 31.0% from the November 30th total of 25,200 shares. Based on an average daily trading volume, of 35,500 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.1% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada during the 3rd quarter worth approximately $77,000. Plato Investment Management Ltd acquired a new stake in Kamada during the third quarter valued at $117,000. Finally, Y.D. More Investments Ltd increased its holdings in Kamada by 1,956.0% in the second quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company's stock valued at $3,643,000 after buying an additional 690,842 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Kamada in a report on Thursday, November 14th.

Kamada Trading Down 2.0 %

Shares of NASDAQ KMDA traded down $0.12 during trading on Friday, reaching $5.91. 19,784 shares of the company traded hands, compared to its average volume of 30,315. The stock has a market cap of $339.71 million, a P/E ratio of 21.11 and a beta of 0.99. The firm's fifty day simple moving average is $5.85 and its 200 day simple moving average is $5.58. Kamada has a 12-month low of $4.74 and a 12-month high of $6.53.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.